PHPSX — Pharmaceuticals
Data updated: 2026-06-22
PHPSX — Pharmaceuticals data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. Leveraged · $3.37M AUM · 2.78% expense ratio · 55.9% 1-yr return. From SEC regulatory filings.
PHPSX Fund Overview
PHPSX — Pharmaceuticals is a US mutual fund managed by ProFunds, categorised as Leveraged. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: ProFunds
- Category: Leveraged
- Assets under management: $3.37M
- 1-year return: 55.9%
- Ticker: PHPSX
- SEC CIK: 0001039803
- SEC series ID: S000003093
- Share class ID: C000008402
PHPSX Holdings
Top 10 holdings of Pharmaceuticals by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Organon & Company | 2.73% |
| Corcept Therapeutics, Inc. | 1.82% |
| Enliven Therapeutics, Inc. | 1.77% |
| Axsome Therapeutics, Inc. | 1.71% |
| Omeros Corp. | 1.61% |
| Perrigo Company PLC | 1.59% |
| Definium Therapeutics, Inc. | 1.55% |
| Nektar Therapeutics | 1.53% |
| Trevi Therapeutics, Inc. | 1.52% |
| Terns Pharmaceuticals, Inc. | 1.49% |
PHPSX Portfolio Allocation
Asset-class allocation of Pharmaceuticals by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 73.3% |
| Cash & Equivalents | 26.9% |
| Derivatives | 0.5% |
PHPSX Performance
Total returns for PHPSX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 2.2% |
| 1 year | 55.9% |
| 3 years (annualised) | 11.1% |
| 5 years (annualised) | 5.5% |
PHPSX Risk Information
Risk metrics for PHPSX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 29.3%
PHPSX Costs and Fees
PHPSX costs about $278 per $10,000 invested per year in fund expenses.
- Net expense ratio: 2.78%
- Gross expense ratio: 3.53%
- Portfolio turnover: 178%
- Brokerage commissions: 3.41 bps of average net assets (SEC N-CEN)
PHPSX Cashflows
Over the 12 months to 2026-04, Pharmaceuticals had net outflows of $1.12M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | $82.64K |
| 2026-03 | −$395.09K |
| 2026-02 | −$300.01K |
| 2026-01 | −$175.64K |
| 2025-12 | −$298.83K |
| 2025-11 | $869.14K |
PHPSX Debt Constituents
No individual debt constituents are reported in Pharmaceuticals's latest SEC N-PORT filing.
PHPSX Prospectus and SEC Filings
Official Pharmaceuticals filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other Leveraged funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.